粪便菌群移植在癌症治疗中的研究进展

doi:10.11904/j.issn.1002-3070.2021.05.01

摘要/Abstract

摘要： 大量研究证明,肠道菌群失衡与人类癌症之间有密切的关系。肠道菌群不仅在维持肠道屏障和代谢营养方面发挥作用,更重要的是,这些微生物有助于调节局部和全身免疫功能,进而参与机体癌症的发病机制。粪便菌群移植(FMT)是一种调节肠道菌群的方法,它的有效机制主要基于有益微生物的增强、微生物组多样性的增加以及正常菌群的恢复。最近有研究表明,以病原体数量明显增加和有益细菌水平相对降低为特征的微生物改变与胃肠道和胃肠道外癌症的发展有关,提示调节肠道菌群是治疗人类癌症具有前景的手段之一。本文围绕FMT在治疗消化系统癌症、非消化系统癌症和癌症相关并发症上的作用展开论述,总结FMT在癌症治疗方面的最新进展。

关键词: 肠道菌群, 粪便菌群移植, 癌症

Abstract: A large number of studies have proved that there is a close relationship between the imbalance of intestinal flora and human cancer.The intestinal flora not only plays a role in maintaining the intestinal barrier and metabolic nutrition,but more importantly,these microorganisms help to regulate local and systemic immune functions,and then participate in the pathogenesis of cancer.Fecal microbiota transplantation(FMT)is a method regulating the intestinal flora.Its effective mechanism is mainly based on the enhancement of beneficial microorganisms,the increase of microbial diversity and the recovery of normal flora.Recent studies have shown that microbial changes characterized by a significant increase in the number of pathogens and a relative decrease in the level of beneficial bacteria are related to the development of gastrointestinal and extra-gastrointestinal cancers,indicating that regulating intestinal flora is one of promising methods for the treatment of human cancer.This article focuses on the role of FMT in the treatment of digestive system cancer,non digestive system cancer and cancer related complications,and summarizes the latest progress of FMT in cancer treatment.

Key words: Intestinal flora, Fecal microbiota transplantation, Cancer

中图分类号:

王恒敏, 赵琦, 吴华星. 粪便菌群移植在癌症治疗中的研究进展[J]. 实用肿瘤学杂志, 2021, 35(5): 468-471.

WANG Hengmin, ZHAO Qi, WU Huaxing. Research progress of fecal microbiota transplantation in cancer treatment[J]. Journal of Practical Oncology, 2021, 35(5): 468-471.

参考文献

1 Zhang X,Zhao S,Song X,et al.Inhibition effect of glycyrrhiza polysaccharide(GCP)on tumor growth through regulation of the gut microbiota composition[J].J Pharmacol Sci,2018,137(4):324-332.
2 Hwang S,Lee CG,Jo M,et al.Enterotoxigenic bacteroides fragilis infection exacerbates tumorigenesis in AOM/DSS mouse model[J].Int J Med Sci,2020,17(2):145-152.
3 Eslami M,Yousefi B,Kokhaei P,et al.Importance of probiotics in the prevention and treatment of colorectal cancer[J].J Cell Physiol,2019,234(10):17127-17143.
4 Bashir A,Miskeen AY,Bhat A,et al.Fusobacterium nucleatum:an emerging bug in colorectal tumorigenesis[J].Eur J Cancer Prev,2015,24(5):373-385.
5 Lam SY,Yu J,Wong SH,et al.The gastrointestinal microbiota and its role in oncogenesis[J].Best Pract Res Clin Gastroenterol,2017,31(6):607-618.
6 Battipaglia G,Malard F,Rubio MT,et al.Fecal microbiota transplantation before or after allogeneic hematopoietic transplantation in patients with hematologic malignancies carrying multidrug-resistance bacteria[J].Haematologica,2019,104(8):1682-1688.
7 Geller LT,Barzily-Rokni M,Danino T,et al.Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine[J].Science,2017,357(6356):1156-1160.
8 Jacouton E,Chain F,Sokol H,et al.Probiotic strain lactobacillus casei BL23 prevents colitis-associated colorectal cancer[J].Front Immunol,2017,8:1553.
9 Zhang F,Cui B,He X,et al.Microbiota transplantation:concept,methodology and strategy for its modernization[J].Protein Cell,2018,9(5):462-473.
10 Santoni M,Piva F,Conti A,et al.Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors[J].Eur Urol,2018,74(4):521-522.
11 Filip M,Tzaneva V,Dumitrascu DL.Fecal transplantation:digestive and extradigestive clinical applications[J].Clujul Med,2018,91(3):259-265.
12 Ma C,Han M,Heinrich B,et al.Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells[J].Science,2018,360(6391):5931.
13 Zhou D,Pan Q,Shen F,et al.Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota[J].Sci Rep,2017,7(1):1529.
14 Ferrere G,Wrzosek L,Cailleux F,et al.Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice[J].J Hepatol,2017,66(4):806-815.
15 Chauhan A,Kumar R,Sharma S,et al.Fecal microbiota transplantation in hepatitis B e antigen-positive chronic hepatitis B patients:a pilot study[J].Dig Dis Sci,2021,66(3):873-880.
16 Mitsuhashi K,Nosho K,Sukawa Y,et al.Association of fusobacterium species in pancreatic cancer tissues with molecular features and prognosis[J].Oncotarget,2015,6(9):7209-7220.
17 Gopalakrishnan V,Spencer CN,Nezi L,et al.Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients[J].Science,2018,359(6371):97-103.
18 Sivan A,Corrales L,Hubert N,et al.Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy[J].Science,2015,350(6264):1084-1089.
19 Chen D,Wu J,Jin D,et al.Fecal microbiota transplantation in cancer management:current status and perspectives[J].Int J Cancer,2019,145(8):2021-2031.
20 Parida S,Sharma D.The microbiome-estrogen connection and breast cancer risk[J].Cells,2019,8(12):1642.
21 Zhu J,Liao M,Yao Z,et al.Breast cancer in postmenopausal women is associated with an altered gut metagenome[J].Microbiome,2018,6(1):136.
22 Mullard A.Oncologists tap the microbiome in bid to improve immunotherapy outcomes[J].Nat Rev Drug Discov,2018,17(3):153-155.
23 Surawicz CM,Brandt LJ,Binion DG,et al.Guidelines for diagnosis,treatment,and prevention of clostridium difficile infections[J].Am J Gastroenterol,2013,108(4):478-498.
24 Konturek PC,Haziri D,Brzozowski T,et al.Emerging role of fecal microbiota therapy in the treatment of gastrointestinal and extra-gastrointestinal diseases[J].J Physiol Pharmacol,2015,66(4):483-491.
25 Gerassy-Vainberg S,Blatt A,Danin-Poleg Y,et al.Radiation induces proinflammatory dysbiosis:transmission of inflammatory susceptibility by host cytokine induction[J].Gut,2018,67(1):97-107.
26 Ding X,Li Q,Li P,et al.Fecal microbiota transplantation:a promising treatment for radiation enteritis?[J].Radiother Oncol,2020,143:12-18.
27 Nie X,Li L,Yi M,et al.The intestinal microbiota plays as a protective regulator against radiation pneumonitis[J].Radiat Res,2020,194(1):52-60.
28 Staffas A,Burgos da Silva M,van den Brink MR.The intestinal microbiota in allogeneic hematopoietic cell transplant and graft-versus-host disease[J].Blood,2017,129(8):927-933.
29 Taur Y,Jenq RR,Perales MA,et al.The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation[J].Blood,2014,124(7):1174-1182.
30 Amrousy DE,El-Afify D,Shabana A.Relationship between bone turnover markers and oxidative stress in children with type 1 diabetes mellitus[J].Pediatr Res,2021,89(4):878-881.
31 Bakken JS,Polgreen PM,Beekmann SE,et al.Treatment approaches including fecal microbiota transplantation for recurrent Clostridium difficile infection(RCDI)among infectious disease physicians[J].Anaerobe,2013,24:20-24.
32 Cammarota G,Ianiro G,Kelly CR,et al.International consensus conference on stool banking for faecal microbiota transplantation in clinical practice[J].Gut,2019,68(12):2111-2121.
33 Ridaura VK,Faith JJ,Rey FE,et al.Gut microbiota from twins discordant for obesity modulate metabolism in mice[J].Science,2013,341(6150):1241214.
34 Li SS,Zhu A,Benes V,et al.Durable coexistence of donor and recipient strains after fecal microbiota transplantation[J].Science,2016,352(6285):586-589.
35 Jalanka J,Mattila E,Jouhten H,et al.Long-term effects on luminal and mucosal microbiota and commonly acquired taxa in faecal microbiota transplantation for recurrent Clostridium difficile infection[J].BMC Med,2016,14(1):155.
36 Le P,Nghiem VT,Mullen PD,et al.Cost-effectiveness of competing treatment strategies for clostridium difficile infection:a systematic review[J].Infect Control Hosp Epidemiol,2018,39(4):412-424.
37 Wang S,Xu M,Wang W,et al.Systematic review:adverse events of fecal microbiota transplantation[J].PLoS One,2016,11(8):e0161174.

[1]	庹吉妤, 张霞, 何晓梅, 姜文珍, 冯觉平, 金霞, 张敏, 魏少忠. 湖北省2018-2019年城市癌症早诊早治项目筛查结果分析[J]. 实用肿瘤学杂志, 2021, 35(4): 297-301.
[2]	李晴雨, 杨雷, 张希, 刘硕, 李慧超, 张倩, 程杨杨, 季加孚, 王宁. 新冠肺炎疫情下癌症早诊早治管理工作探讨[J]. 实用肿瘤学杂志, 2021, 35(4): 302-306.
[3]	果思伽, 刘家仁. 植物化学物在癌症化学预防中的作用[J]. 实用肿瘤学杂志, 2020, 34(5): 460-465.
[4]	庞晨, 张秀玲, 张锡流. 铁皮石斛抑制上皮源性恶性肿瘤的研究进展[J]. 实用肿瘤学杂志, 2020, 34(4): 362-367.
[5]	张玫茵娄阁. N6-甲基腺嘌呤与癌症的研究进展[J]. 实用肿瘤学杂志, 2019, 33(4): 357-360.
[6]	石小康, 丁佑铭, 汪斌, 余斌, 徐雨. UBE2T在原发性肝癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(2): 128-133.
[7]	马超(综述), 王国年(审校). 麻醉药物对围术期癌症患者免疫功能的影响[J]. 实用肿瘤学杂志, 2018, 32(3): 285-288.
[8]	张中民, 庞达. 长链非编码RNA调控癌症细胞信号通路的研究进展[J]. 实用肿瘤学杂志, 2018, 32(2): 184-188.
[9]	赵倩妤, 孙轶华. 拉曼光谱在癌症组织学诊断中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(1): 92-96.
[10]	顾秀瑛，顾晓芬，朱俊宇，周天虹，朱琳. 2014-2016年乌鲁木齐市9265例城市居民肺癌筛查结果分析[J]. 实用肿瘤学杂志, 2017, 31(3): 242-245.
[11]	李根英，综述，张云艳，审校. MTBP与癌症的研究进展[J]. 实用肿瘤学杂志, 2016, 30(6): 560-562.
[12]	周海平, 李水富, 张延红, 王峻巍, 常琳, 高晓波, 陈万青. 癌症预防经济状况分析[J]. 实用肿瘤学杂志, 2016, 30(3): 249-252.
[13]	孙惠昕,陈王洋,宋冰冰. 黑龙江省2013—2014年度城市癌症筛查分析[J]. 实用肿瘤学杂志, 2015, 29(4): 315-318.
[14]	吕研¹, 李文鑫¹, 李剑¹综述, 徐向英^1,2审校. 非小细胞肺癌放化疗后局部复发再程放疗的研究进展[J]. 实用肿瘤学杂志, 2015, 29(3): 259-262.
[15]	刘谦,王桂茹. 保护治疗是根除癌症卫士和新医学模式的探讨[J]. 实用肿瘤学杂志, 2013, 27(3): 285-288.